These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 31829284)
21. Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53. Ghaleb A; Yallowitz A; Marchenko N Commun Biol; 2019; 2():436. PubMed ID: 31799437 [TBL] [Abstract][Full Text] [Related]
22. Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. Palaniappan M; Edwards D; Creighton CJ; Medina D; Conneely OM PLoS One; 2018; 13(3):e0194913. PubMed ID: 29590203 [TBL] [Abstract][Full Text] [Related]
23. HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53. Klein A; Guhl E; Tzeng YJ; Fuhrhop J; Levrero M; Graessmann M; Graessmann A Oncogene; 2003 May; 22(19):2910-9. PubMed ID: 12771941 [TBL] [Abstract][Full Text] [Related]
24. c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. Morrison CD; Allington TM; Thompson CL; Gilmore HL; Chang JC; Keri RA; Schiemann WP Oncotarget; 2016 Nov; 7(45):72777-72794. PubMed ID: 27626309 [TBL] [Abstract][Full Text] [Related]
25. Roles of BCCIP deficiency in mammary tumorigenesis. Droz-Rosario R; Lu H; Liu J; Liu NA; Ganesan S; Xia B; Haffty BG; Shen Z Breast Cancer Res; 2017 Oct; 19(1):115. PubMed ID: 29047390 [TBL] [Abstract][Full Text] [Related]
26. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression. Wani G; Noyes I; Milo GE; D'Ambrosio SM Mol Med; 1997 Apr; 3(4):273-83. PubMed ID: 9131589 [TBL] [Abstract][Full Text] [Related]
27. [Relationship between expressions of telomerase genes and apoptosis related genes in mammary ductal atypical hyperplasia]. Song M; Li BL; Mi XY; Gao YX; Song JY Ai Zheng; 2002 May; 21(5):484-8. PubMed ID: 12452037 [TBL] [Abstract][Full Text] [Related]
28. Human Spy1 promotes survival of mammalian cells following DNA damage. Barnes EA; Porter LA; Lenormand JL; Dellinger RW; Donoghue DJ Cancer Res; 2003 Jul; 63(13):3701-7. PubMed ID: 12839962 [TBL] [Abstract][Full Text] [Related]
29. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Arima Y; Hirota T; Bronner C; Mousli M; Fujiwara T; Niwa S; Ishikawa H; Saya H Genes Cells; 2004 Feb; 9(2):131-42. PubMed ID: 15009091 [TBL] [Abstract][Full Text] [Related]
30. Zinc-finger protein p52-ZER6 accelerates colorectal cancer cell proliferation and tumour progression through promoting p53 ubiquitination. Huang C; Wu S; Li W; Herkilini A; Miyagishi M; Zhao H; Kasim V EBioMedicine; 2019 Oct; 48():248-263. PubMed ID: 31521611 [TBL] [Abstract][Full Text] [Related]
31. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints. Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036 [TBL] [Abstract][Full Text] [Related]
32. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. Cannell IG; Merrick KA; Morandell S; Zhu CQ; Braun CJ; Grant RA; Cameron ER; Tsao MS; Hemann MT; Yaffe MB Cancer Cell; 2015 Nov; 28(5):623-637. PubMed ID: 26602816 [TBL] [Abstract][Full Text] [Related]
33. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Lu X; Liu DP; Xu Y Oncogene; 2013 Jun; 32(23):2900-6. PubMed ID: 22824795 [TBL] [Abstract][Full Text] [Related]
34. Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2. Porter LA; Dellinger RW; Tynan JA; Barnes EA; Kong M; Lenormand JL; Donoghue DJ J Cell Biol; 2002 Apr; 157(3):357-66. PubMed ID: 11980914 [TBL] [Abstract][Full Text] [Related]
35. Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. Reimer CL; Borras AM; Kurdistani SK; Garreau JR; Chung M; Aaronson SA; Lee SW J Biol Chem; 1999 Apr; 274(16):11022-9. PubMed ID: 10196184 [TBL] [Abstract][Full Text] [Related]
36. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872 [TBL] [Abstract][Full Text] [Related]
37. Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time. Bukholm IR; Husdal A; Nesland JM; Langerød A; Bukholm G Breast Cancer Res Treat; 2003 Jul; 80(2):199-206. PubMed ID: 12908823 [TBL] [Abstract][Full Text] [Related]
38. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Liao DJ; Natarajan G; Deming SL; Jamerson MH; Johnson M; Chepko G; Dickson RB Oncogene; 2000 Mar; 19(10):1307-17. PubMed ID: 10713672 [TBL] [Abstract][Full Text] [Related]
39. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. Innocente SA; Lee JM FEBS Lett; 2005 Feb; 579(5):1001-7. PubMed ID: 15710382 [TBL] [Abstract][Full Text] [Related]
40. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; López-García MÁ; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ J Pathol; 2014 Jun; 233(2):124-37. PubMed ID: 24615332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]